Charles River Laboratories International, Inc. (NYSE: CRL) Stock Competitors & Peer Comparison
See CRL's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CRL and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CRL | $291.76 | -0.37% | 14.2B | 29.77 | $9.90 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.63% |
| TMO | $674.21 | -0.12% | 250.9B | 29.30 | $23.16 | +0.27% |
| DHR | $224.45 | -0.02% | 159.9B | 28.50 | $7.98 | +0.63% |
| NTRA | $411.85 | -0.17% | 59B | -311.95 | -$1.32 | N/A |
| A | $174.94 | +1.24% | 49.5B | 30.15 | $5.81 | +0.58% |
| IQV | $268.57 | -0.67% | 44.6B | 22.32 | $12.13 | N/A |
| WAT | $441.58 | +1.85% | 43.5B | 32.38 | $13.68 | N/A |
| IDXX | $530.13 | +2.09% | 41.7B | 37.21 | $14.22 | N/A |
| ILMN | $268.83 | -0.43% | 41.1B | 54.06 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
CRL vs DHR-PB Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CRL's ROE is -0.08%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, CRL is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for CRL.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
CRL vs TMO Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, TMO has a market cap of 250.9B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while TMO trades at $674.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas TMO's P/E ratio is 29.30. In terms of profitability, CRL's ROE is -0.08%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CRL is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for CRL.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
CRL vs DHR Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, DHR has a market cap of 159.9B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while DHR trades at $224.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas DHR's P/E ratio is 28.50. In terms of profitability, CRL's ROE is -0.08%, compared to DHR's ROE of +0.08%. Regarding short-term risk, CRL is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for CRL.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
CRL vs NTRA Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, NTRA has a market cap of 59B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while NTRA trades at $411.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas NTRA's P/E ratio is -311.95. In terms of profitability, CRL's ROE is -0.08%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, CRL is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for CRL.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
CRL vs A Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, A has a market cap of 49.5B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while A trades at $174.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas A's P/E ratio is 30.15. In terms of profitability, CRL's ROE is -0.08%, compared to A's ROE of +0.20%. Regarding short-term risk, CRL is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for CRL.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
CRL vs IQV Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, IQV has a market cap of 44.6B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while IQV trades at $268.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas IQV's P/E ratio is 22.32. In terms of profitability, CRL's ROE is -0.08%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CRL is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for CRL.Check IQV's competition here
Waters Corporation (NYSE: WAT)
CRL vs WAT Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while WAT trades at $441.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas WAT's P/E ratio is 32.38. In terms of profitability, CRL's ROE is -0.08%, compared to WAT's ROE of +0.02%. Regarding short-term risk, CRL is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for CRL.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
CRL vs IDXX Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, IDXX has a market cap of 41.7B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while IDXX trades at $530.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas IDXX's P/E ratio is 37.21. In terms of profitability, CRL's ROE is -0.08%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, CRL is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for CRL.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
CRL vs ILMN Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, ILMN has a market cap of 41.1B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while ILMN trades at $268.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas ILMN's P/E ratio is 54.06. In terms of profitability, CRL's ROE is -0.08%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, CRL is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for CRL.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
CRL vs MTD Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, MTD has a market cap of 31.2B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while MTD trades at $1,527.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas MTD's P/E ratio is 35.50. In terms of profitability, CRL's ROE is -0.08%, compared to MTD's ROE of -12.00%. Regarding short-term risk, CRL is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for CRL.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
CRL vs DGX Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, DGX has a market cap of 26.2B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while DGX trades at $233.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas DGX's P/E ratio is 23.44. In terms of profitability, CRL's ROE is -0.08%, compared to DGX's ROE of +0.14%. Regarding short-term risk, CRL is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for CRL.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
CRL vs LH Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while LH trades at $307.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas LH's P/E ratio is 18.37. In terms of profitability, CRL's ROE is -0.08%, compared to LH's ROE of +0.12%. Regarding short-term risk, CRL is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for CRL.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
CRL vs GH Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, GH has a market cap of 23.8B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while GH trades at $175.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas GH's P/E ratio is -50.81. In terms of profitability, CRL's ROE is -0.08%, compared to GH's ROE of +2.11%. Regarding short-term risk, CRL is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for CRL.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
CRL vs EXAS Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CRL's ROE is -0.08%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, CRL is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for CRL.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
CRL vs MEDP Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, MEDP has a market cap of 17.2B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while MEDP trades at $617.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas MEDP's P/E ratio is 36.10. In terms of profitability, CRL's ROE is -0.08%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, CRL is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for CRL.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
CRL vs ILMNV Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas ILMNV's P/E ratio is N/A. In terms of profitability, CRL's ROE is -0.08%, compared to ILMNV's ROE of N/A. Regarding short-term risk, CRL is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for CRL.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
CRL vs RVTY Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, RVTY has a market cap of 16.8B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while RVTY trades at $151.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas RVTY's P/E ratio is 28.22. In terms of profitability, CRL's ROE is -0.08%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, CRL is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for CRL.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
CRL vs PKI Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas PKI's P/E ratio is 41.45. In terms of profitability, CRL's ROE is -0.08%, compared to PKI's ROE of +0.03%. Regarding short-term risk, CRL is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for CRL.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
CRL vs ICLR Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, ICLR has a market cap of 13.4B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while ICLR trades at $170.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas ICLR's P/E ratio is 14.32. In terms of profitability, CRL's ROE is -0.08%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, CRL is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for CRL.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
CRL vs QGEN Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, QGEN has a market cap of 9.3B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while QGEN trades at $44.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas QGEN's P/E ratio is 18.60. In terms of profitability, CRL's ROE is -0.08%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, CRL is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for CRL.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
CRL vs GRAL Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while GRAL trades at $133.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas GRAL's P/E ratio is -13.60. In terms of profitability, CRL's ROE is -0.08%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, CRL is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for CRL.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
CRL vs RDNT Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while RDNT trades at $69.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas RDNT's P/E ratio is 156.11. In terms of profitability, CRL's ROE is -0.08%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, CRL is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for CRL.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
CRL vs BLLN Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, BLLN has a market cap of 5.6B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while BLLN trades at $121.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas BLLN's P/E ratio is 173.89. In terms of profitability, CRL's ROE is -0.08%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, CRL is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for CRL.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
CRL vs SHC Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while SHC trades at $18.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas SHC's P/E ratio is 19.22. In terms of profitability, CRL's ROE is -0.08%, compared to SHC's ROE of +0.27%. Regarding short-term risk, CRL is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for CRL.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
CRL vs SYNH Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CRL's ROE is -0.08%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CRL is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for CRL.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
CRL vs VCYT Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while VCYT trades at $45.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas VCYT's P/E ratio is 22.62. In terms of profitability, CRL's ROE is -0.08%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, CRL is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for CRL.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
CRL vs CDNA Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while CDNA trades at $63.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas CDNA's P/E ratio is 76.90. In terms of profitability, CRL's ROE is -0.08%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, CRL is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for CRL.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
CRL vs OLK Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas OLK's P/E ratio is -96.59. In terms of profitability, CRL's ROE is -0.08%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CRL is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for CRL.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
CRL vs WGS Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while WGS trades at $77.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas WGS's P/E ratio is 238.69. In terms of profitability, CRL's ROE is -0.08%, compared to WGS's ROE of -0.39%. Regarding short-term risk, CRL is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for CRL.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
CRL vs PSNL Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while PSNL trades at $16.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas PSNL's P/E ratio is -14.97. In terms of profitability, CRL's ROE is -0.08%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, CRL is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for CRL.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
CRL vs OPK Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas OPK's P/E ratio is -6.04. In terms of profitability, CRL's ROE is -0.08%, compared to OPK's ROE of -0.06%. Regarding short-term risk, CRL is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for CRL.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
CRL vs CSTL Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while CSTL trades at $34.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas CSTL's P/E ratio is -54.44. In terms of profitability, CRL's ROE is -0.08%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, CRL is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for CRL.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
CRL vs FLGT Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, FLGT has a market cap of 635M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while FLGT trades at $22.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas FLGT's P/E ratio is 2236.00. In terms of profitability, CRL's ROE is -0.08%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, CRL is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for CRL.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
CRL vs GRALV Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas GRALV's P/E ratio is N/A. In terms of profitability, CRL's ROE is -0.08%, compared to GRALV's ROE of N/A. Regarding short-term risk, CRL is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for CRL.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
CRL vs NEO Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, NEO has a market cap of 495.7M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while NEO trades at $18.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas NEO's P/E ratio is 148.38. In terms of profitability, CRL's ROE is -0.08%, compared to NEO's ROE of -0.06%. Regarding short-term risk, CRL is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for CRL.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
CRL vs MYGN Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, MYGN has a market cap of 400.5M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while MYGN trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas MYGN's P/E ratio is -32.62. In terms of profitability, CRL's ROE is -0.08%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, CRL is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for CRL.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
CRL vs CO Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas CO's P/E ratio is 5.06. In terms of profitability, CRL's ROE is -0.08%, compared to CO's ROE of +0.11%. Regarding short-term risk, CRL is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for CRL.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
CRL vs FLDM Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CRL's ROE is -0.08%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, CRL is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for CRL.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
CRL vs BDSX Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, BDSX has a market cap of 247.6M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while BDSX trades at $29.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas BDSX's P/E ratio is -9.60. In terms of profitability, CRL's ROE is -0.08%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, CRL is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for CRL.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
CRL vs XGN Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, XGN has a market cap of 204.9M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while XGN trades at $8.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas XGN's P/E ratio is -10.47. In terms of profitability, CRL's ROE is -0.08%, compared to XGN's ROE of -1.22%. Regarding short-term risk, CRL is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for CRL.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
CRL vs FRNM Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, FRNM has a market cap of 132.1M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while FRNM trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas FRNM's P/E ratio is N/A. In terms of profitability, CRL's ROE is -0.08%, compared to FRNM's ROE of N/A. Regarding short-term risk, CRL is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for CRL.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
CRL vs GTH Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas GTH's P/E ratio is -1.11. In terms of profitability, CRL's ROE is -0.08%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CRL is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for CRL.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
CRL vs GENE Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas GENE's P/E ratio is -38.25. In terms of profitability, CRL's ROE is -0.08%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CRL is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for CRL.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
CRL vs IMDX Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, IMDX has a market cap of 102.7M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while IMDX trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas IMDX's P/E ratio is -2.13. In terms of profitability, CRL's ROE is -0.08%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, CRL is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for CRL.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
CRL vs SERA Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, SERA has a market cap of 77.1M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while SERA trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas SERA's P/E ratio is -3.11. In terms of profitability, CRL's ROE is -0.08%, compared to SERA's ROE of -0.47%. Regarding short-term risk, CRL is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for CRL.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
CRL vs PRPO Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, PRPO has a market cap of 43M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while PRPO trades at $23.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas PRPO's P/E ratio is -37.09. In terms of profitability, CRL's ROE is -0.08%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, CRL is similarly volatile compared to PRPO. This indicates similar risk in terms of short-term price fluctuations for CRL.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
CRL vs QUCY Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, QUCY has a market cap of 31.2M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas QUCY's P/E ratio is -0.06. In terms of profitability, CRL's ROE is -0.08%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, CRL is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for CRL.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
CRL vs MDXH Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, MDXH has a market cap of 28.1M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while MDXH trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas MDXH's P/E ratio is -0.75. In terms of profitability, CRL's ROE is -0.08%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, CRL is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for CRL.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
CRL vs AKU Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas AKU's P/E ratio is -0.13. In terms of profitability, CRL's ROE is -0.08%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CRL is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for CRL.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
CRL vs BNR Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, BNR has a market cap of 18.6M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while BNR trades at $18.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas BNR's P/E ratio is -20.26. In terms of profitability, CRL's ROE is -0.08%, compared to BNR's ROE of -0.13%. Regarding short-term risk, CRL is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for CRL.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
CRL vs CEMI Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas CEMI's P/E ratio is -0.63. In terms of profitability, CRL's ROE is -0.08%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, CRL is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for CRL.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
CRL vs ENZ Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CRL's ROE is -0.08%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CRL is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for CRL.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
CRL vs PMD Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas PMD's P/E ratio is -5.24. In terms of profitability, CRL's ROE is -0.08%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CRL is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for CRL.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
CRL vs ME Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas ME's P/E ratio is -0.03. In terms of profitability, CRL's ROE is -0.08%, compared to ME's ROE of -42.03%. Regarding short-term risk, CRL is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for CRL.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
CRL vs MYNZ Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, CRL's ROE is -0.08%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, CRL is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for CRL.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
CRL vs CHEK Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas CHEK's P/E ratio is -0.43. In terms of profitability, CRL's ROE is -0.08%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, CRL is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for CRL.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
CRL vs BIAFW Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, BIAFW has a market cap of 9.8M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while BIAFW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas BIAFW's P/E ratio is 1.04. In terms of profitability, CRL's ROE is -0.08%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, CRL is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for CRL.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
CRL vs CNTG Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CRL's ROE is -0.08%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CRL is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for CRL.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
CRL vs ADVB Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while ADVB trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas ADVB's P/E ratio is -61.18. In terms of profitability, CRL's ROE is -0.08%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, CRL is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for CRL.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
CRL vs NDRA Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while NDRA trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas NDRA's P/E ratio is -0.88. In terms of profitability, CRL's ROE is -0.08%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, CRL is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for CRL.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
CRL vs APDN Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas APDN's P/E ratio is -0.10. In terms of profitability, CRL's ROE is -0.08%, compared to APDN's ROE of -7.23%. Regarding short-term risk, CRL is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for CRL.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
CRL vs NVTA Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CRL's ROE is -0.08%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CRL is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for CRL.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
CRL vs LMDXW Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CRL's ROE is -0.08%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CRL is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for CRL.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
CRL vs LMDX Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CRL's ROE is -0.08%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CRL is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for CRL.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
CRL vs DMTK Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CRL's ROE is -0.08%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CRL is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for CRL.Check DMTK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
CRL vs BIAF Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, BIAF has a market cap of 3.1M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while BIAF trades at $6.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas BIAF's P/E ratio is -0.87. In terms of profitability, CRL's ROE is -0.08%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, CRL is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for CRL.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
CRL vs NOTV Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas NOTV's P/E ratio is -0.03. In terms of profitability, CRL's ROE is -0.08%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CRL is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for CRL.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
CRL vs SQL Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas SQL's P/E ratio is -0.40. In terms of profitability, CRL's ROE is -0.08%, compared to SQL's ROE of -30.46%. Regarding short-term risk, CRL is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for CRL.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
CRL vs AWH Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas AWH's P/E ratio is -0.09. In terms of profitability, CRL's ROE is -0.08%, compared to AWH's ROE of +1.62%. Regarding short-term risk, CRL is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for CRL.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
CRL vs HTGM Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CRL's ROE is -0.08%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CRL is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for CRL.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
CRL vs BIOC Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CRL's ROE is -0.08%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CRL is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for CRL.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
CRL vs SQLLW Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, CRL's ROE is -0.08%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, CRL is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for CRL.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
CRL vs ISPC Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, ISPC has a market cap of 165.2K. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while ISPC trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas ISPC's P/E ratio is -0.04. In terms of profitability, CRL's ROE is -0.08%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, CRL is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for CRL.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
CRL vs WGSWW Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, CRL's ROE is -0.08%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, CRL is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for CRL.Check WGSWW's competition here
Danaher Corporation (NYSE: DHR-PA)
CRL vs DHR-PA Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CRL's ROE is -0.08%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, CRL is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for CRL.Check DHR-PA's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
CRL vs BNGOW Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CRL's ROE is -0.08%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, CRL is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for CRL.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
CRL vs NDRAW Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CRL's ROE is -0.08%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, CRL is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for CRL.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
CRL vs CHEKZ Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CRL's ROE is -0.08%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CRL is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for CRL.Check CHEKZ's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
CRL vs PRXL Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas PRXL's P/E ratio is 42.97. In terms of profitability, CRL's ROE is -0.08%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CRL is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for CRL.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
CRL vs OCDX Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CRL's ROE is -0.08%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CRL is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for CRL.Check OCDX's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
CRL vs MEUSW Comparison September 2026
Charles River Laboratories International, Inc. (NYSE: CRL) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRL stands at 14.2B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CRL is priced at $291.76 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRL currently has a P/E ratio of 29.77, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CRL's ROE is -0.08%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, CRL is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for CRL.Check MEUSW's competition here